Nuvectis Pharma Inc. (NVCT)
5.52
-0.12 (-2.13%)
At close: Jan 15, 2025, 12:02 PM
undefined% (undefined)
| Bid | 5.51 |
| Market Cap | 106.65M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -4.76 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.65 |
| Volume | 56,085 |
| Avg. Volume (20D) | 185,309 |
| Open | 5.71 |
| Previous Close | 5.64 |
| Day's Range | 5.40 - 5.75 |
| 52-Week Range | 4.44 - 12.10 |
| Beta | undefined |
About NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey....
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2022
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NVCT
Website https://www.nuvectis.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NVCT stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 280.43% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-46.3%
Nuvectis Pharma shares are trading lower. The comp...
Unlock content with
Pro Subscription
2 months ago ·
Source
+17.75%
Nuvectis Pharma shares are trading higher after the company reported better-than-expected Q3 EPS results.
